The Developmental Origins of Endometriosis
NCT05951452
· ctgov
completed
- Enrollment
- 40
- Start
- 2024-01-08
- Completion
- 2026-06-17
- Last updated
- 2026-06-18
- Has results
- False
- Countries
- France
Conditions
Tagged with
Interventions
-
Blood samples for testosterone and SHBG measurements
OTHER
Several measurements of the testosterone concentration will be performed on serum from 10 mL of blood collected at: * t0 corresponding to the start of the hospital appointment and before watching the video * t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video
-
Saliva samples for oxytocin measurements
OTHER
Several measurements of the oxytocin concentration will be performed on 2 ml saliva samples: * t0 corresponding to 20 minutes after the start of the hospital appointment and before watching the video * t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video
Eligibility criteria
Inclusion Criteria:
* Nulliparous woman
* No hormonal contraception for at least 3 months
* Regular menstrual cycles (between 26 and 32 days) or proven ovulation (positive urine ovulation test ovulation test or progesterone level \>3 ng/ml in the luteal phase)
* Normal BMI (≥ 18,5 and \< 30 kg/m²)
Specific criteria (ENDO+ group) :
* Stage III or IV endometriosis confirmed by laparoscopy or by laparotomy or MRI
* Painful symptoms
Specific criteria (ENDO- group) :
• Patient without endometriosis confirmed by laparoscopy
Exclusion Criteria:
* Ovarian stimulation planned within 3 months
* Adenomyosis
* Use of a copper coil
* Polycystic ovary syndrome
* Pudendal neuralgia
* Episiotomy or lesion of the posterior perineum that may modify AGD
* Diabetes or thyroid disease
* Chronic liver failure, chronic renal failure, cardiac pathology, autoimmune disease
* Autism
* Diagnosis and/or treatment for psychiatric illness
* Chronic exposure to cocaine, methamphetamine, morphine or ecstasy within 30 days before the inclusion visit
* Chronic exposure to Tetrahydrocannabinol (THC) within 7 days prior to inclusion.
* Patient on treatment(s) that vary oxytocin (e.g. atosiban), testosterone or GnRH
* Pregnant or breast-feeding patient
* Patients who have given birth or breastfed within 6 weeks before the inclusion visit
* Patient unable to read French
* Failure to obtain informed consent
* Patient not affiliated with or not benefiting from a national health insurance scheme
* Person under legal protection, guardianship or curatorship
* Patient participating in other research involving the human person
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine